4D Molecular Therapeutics's three largest insider shareholders as of May 30, 2026 are Capital Management, L.P. Ra (TenPercentOwner, 4.56Mn shares), Global Investors Lp Viking (TenPercentOwner, 4.25Mn shares), David Kirn (Chief Executive Officer, 1.06Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Partners L P/Il Bvf | - | 87,911 | 0 | 13 Nov, 2024 |
| Global Investors Lp Viking | - | 0 | 4,247,914 | 05 Jan, 2024 |
| August J Moretti | Chief Financial Officer | 11,045 | 0 | 16 May, 2023 |
| Capital Management, L.P. Ra | - | 0 | 4,563,211 | 10 Dec, 2024 |
| Charles Theuer | - | 41,684 | 0 | 16 Dec, 2025 |
| David Kirn | Chief Executive Officer | 1,059,153 | 0 | 12 Jul, 2024 |
| Scott Bizily | Chief Legal Officer | 3,594 | 0 | 19 Dec, 2025 |
| Robert Young Kim | Chief Medical Officer | 1,043 | 0 | 07 Feb, 2024 |
| Ashoo Gupta | Vp, Finance And Controller | 47,055 | 0 | 24 Mar, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 25 Mar, 2026 | David Kirn | Stock Option (Right to Buy) | A | 750,000 | $0.00 | 750,000 | D | A |
| 25 Mar, 2026 | Christopher Paul Simms | Stock Option (Right to Buy) | A | 219,000 | $0.00 | 219,000 | D | A |
| 25 Mar, 2026 | Scott Bizily | Stock Option (Right to Buy) | A | 217,000 | $0.00 | 217,000 | D | A |
| 25 Mar, 2026 | Christopher Paul Simms | Stock Option (Right to Buy) | A | 219,000 | $0.00 | 219,000 | D | A |
| 25 Mar, 2026 | Scott Bizily | Stock Option (Right to Buy) | A | 217,000 | $0.00 | 217,000 | D | A |
| 25 Mar, 2026 | David Kirn | Stock Option (Right to Buy) | A | 750,000 | $0.00 | 750,000 | D | A |
| 20 Mar, 2026 | Ashoo Gupta | Common Stock | A | 865 | - | 47,224 | D | M |
| 20 Mar, 2026 | Ashoo Gupta | Common Stock | A | 865 | - | 47,224 | D | M |
| 20 Mar, 2026 | Ashoo Gupta | Common Stock | D | 310 | $8.61 | 46,914 | D | S |
| 20 Mar, 2026 | Ashoo Gupta | Common Stock | D | 310 | $8.61 | 46,914 | D | S |
| 20 Mar, 2026 | Ashoo Gupta | Common Stock | A | 221 | - | 47,135 | D | M |
| 20 Mar, 2026 | Ashoo Gupta | Common Stock | A | 221 | - | 47,135 | D | M |
| 20 Mar, 2026 | Ashoo Gupta | Common Stock | D | 80 | $8.61 | 47,055 | D | S |
| 20 Mar, 2026 | Ashoo Gupta | Common Stock | D | 80 | $8.61 | 47,055 | D | S |
| 20 Mar, 2026 | Ashoo Gupta | Restricted Stock Units | D | 865 | $0.00 | 12,119 | D | M |
| 20 Mar, 2026 | Ashoo Gupta | Restricted Stock Units | D | 865 | $0.00 | 12,119 | D | M |
| 20 Mar, 2026 | Ashoo Gupta | Restricted Stock Units | D | 221 | $0.00 | 3,087 | D | M |
| 20 Mar, 2026 | Ashoo Gupta | Restricted Stock Units | D | 221 | $0.00 | 3,087 | D | M |
| 05 Jan, 2026 | Glenn Sblendorio | Stock Option (Right to Buy) | A | 45,000 | $0.00 | 45,000 | D | A |
| 05 Jan, 2026 | Glenn Sblendorio | Stock Option (Right to Buy) | A | 45,000 | $0.00 | 45,000 | D | A |